comparemela.com

Latest Breaking News On - Pharmadrug inc - Page 13 : comparemela.com

PharmaDrug Inc : PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Toronto, Ontario (Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

United statesWangy cepharanthineDaniel cohenPharmadrug incDrug administrationNational cancer institute surveillanceNewsfile corpAustralia therapeutic goods administrationAustralia researchGenvion corporationAmerican cancer societyTherapeutic goods administrationEnteric coated oral cepharanthineValidated studies reveal potentialEnabling esophageal cancerSairiyo therapeutics

PharmaDrug Inc unveils plans for first-in-human clinical study with its lead drug candidate PD-001 in esophageal cancer

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) revealed that it intends to pursue a first-in-human study of its lead drug candidate cepharanthine-2HCL (PD-001) for.

Daniel cohenAustralia therapeutic goods administrationPharmadrug incAustralia researchDrug administrationGenvion corporationTherapeutic goods administrationInvestigational new drugCurrent good manufacturing practice

PharmaDrug Inc : PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Toronto, Ontario (Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

United statesWangy cepharanthineDaniel cohenBaillyc cepharanthineNewsfile corpDevelopment paths for oncologyPharmadrug incDrug administrationPatent cooperation treatySet forthCentered around demonstrated benefitPre clinical prostate cancerProvisional patentValidated studies support potentialDevelopment pathsInfectious disease create

PharmaDrug Inc files patent cooperation treaty for PD-001 as a treatment for prostate cancer, opening window to pursue protection in 153 countries

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) has filed a patent cooperation treaty (PCT) application for its lead drug cepharanthine-2HCL (PD-001) for the.

United statesDaniel cohenPharmadrug inc

PharmaDrug Advances Programs in Oncology and Infectious Disease through Completion of cGMP Drug Substance Manufacturing

Toronto - PharmaDrug Inc. , a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to. | October 5, 2022

United statesDaniel cohenDevelopment paths for oncologyPharmadrug incDrug administrationGenvion corporationDevelopment pathsInfectious disease createEnteric coated oral cepharanthineValidated studies reveal potentialEnabling prostate cancerProvisional patentSairiyo therapeuticsSuper smartNews publishingPharmadrug inc stock exchange

vimarsana © 2020. All Rights Reserved.